GlycoEra AG is advancing glycoengineered therapeutics to address unmet medical needs. Despite significant advancements in understanding the role of glycans in human health and diseases, this knowledge has not translated well into therapeutic drug development, a consequence of the limitations and complexities of controlling glycosylation processes. GlycoEra’s platform has overcome these challenges! The CustomGlycan Platform enables glycan-mediated modes of action through the engineering of highly defined specific glycan structures, accessing a novel combinatorial dimension for the treatment of very challenging diseases.
Get in touch with us if you would like to be part of this amazing new era in therapeutic drug development!
Get in touch with us if you would like to be part of this amazing new era in therapeutic drug development!
Location: Switzerland
Employees: 11-50
Total raised: $790.81M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 25.11.2021 | 5AM Ventur... | 5amventure... |
| 09.05.2025 | Catalio Ca... | cataliocap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 11.09.2025 | Series B | $611.07M | - |
| 27.05.2025 | - | $130M | - |
| 11.11.2021 | Series A | $49.74M | - |
Mentions in press and media 23
| Date | Title | Description |
| 31.03.2026 | Five deep-tech pioneers shortlisted for the ZKB Pionierpreis Technopark 2026 | The jury of the ZKB Pionierpreis Technopark has selected the five finalists for the 2026 edition of one of Switzerland’s leading deep-tech startup awards. The decision was made during the last jury meeting chaired by Lothar Thiele, who pre... |
| 12.03.2026 | From scientific excellence to global startups: the Swiss tech ecosystem | Switzerland’s tech ecosystem in 2025 showed strong resilience and continued specialisation in deep technology, life sciences, climate innovation, and industrial AI. Startups across the country attracted €3.3 billion in funding through hundr... |
| 20.01.2026 | ZKB Pionierpreis Technopark presents shortlist | From a record 76 applications, the eight-member jury of the 2026 edition of the ZKB Pionierpreis Technopark award competition shortlisted 13 startups whose technologies demonstrate strong innovation potential and clear paths toward market ... |
| 12.01.2026 | Switzerland's Biotech Surge: Windward Bio Secures Funding, Forges Global Drug Deal Amidst Venturelab's Record Year | Swiss innovation is surging. Venturelab, a key accelerator, empowered over 6,700 entrepreneurs in 2025. It propelled Swiss startups to raise billions in funding. Biotech leader Windward Bio exemplified this success. The company secured a si... |
| 23.12.2025 | Venturelab 2025: Powering Over 6,700 Entrepreneurs | 23.12.2025 13:40, Rita Longobardi 2025 was a record-breaking year for Venturelab, delivering 544 days of training, workshops, and international programs to 6,700 entrepreneurs and driving Swiss startups to raise billions. From Venture Kick ... |
| 15.09.2025 | Europe's VC Shift: UK Fights for Lead as Healthtech Soars in 2025 | European venture capital is undergoing significant shifts in 2025. The UK remains a leader, but emerging competition from Germany and France is notable. Healthtech and AI innovation are major investment drivers, securing billions across the... |
| 11.09.2025 | Europe's 10 biggest healthtech deals in H1 2025 | Healthtech continued to demonstrate its strength in Europe in the first half of 2025, attracting €4 billion in funding, around 12 per cent of the €33.7 billion raised across all European tech sectors. Although healthtech accounted for just ... |
| 10.06.2025 | May 2025's top 10 European tech deals you need to know about | In May, European tech companies raised a total of €5.5 billion across 341 deals, a 66.7% increase from April’s €3.3 billion and 311 deals. Despite the month-on-month growth, the figure remains 48% lower than May 2024, reflecting ongoing inv... |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 30.05.2025 | Grammarly raises $1B, angel fund ‘Masia’ aims to cement Barcelona’s tech hub status, and cryogenic pets | This week we tracked more than 75 tech funding deals worth over €1.9 billion, and over 5 exits, M&A transactions, rumours, and related news stories across Europe. If email is more your thing, you can always subscribe to our newsletter a... |
Show more